Lupin - U.S.FDA Warning Letter For Somerset Facility Will Not Disrupt Supplies Or Revenues: Centrum Broking

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Centrum Broking Report

Lupin Ltd. has received a warning letter from the U.S. Food and Drug Administration for its Somerset, New Jersey facility, which contributes ~5% of its global sales.

The two-month long inspection was due to an active Covid-19 case in the facility.

The warning letter would not disrupt supplies or impact existing revenues from this facility.

It is noteworthy that the U.S.FDA has had similar observations on this facility earlier and other facilities of the company.

We anticipate a 12-18 months’ resolution time as of now. Also, expect additional remediation costs would impact margins.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.